Barclays’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Barclays's CTMX Position: Q3 2026 in Review
Barclays increased its CytomX Therapeutics (CTMX) stake by 349% in Q3 2026, buying an estimated $1.47M and bringing the position to 568,003 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2759.
Barclays first reported a position in CTMX in Q4 2015 and has held it in 31 quarters since. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Barclays held 568,003 shares of CytomX Therapeutics worth $1.54M as of Q3 2026.
- Barclays bought 441,588 CytomX Therapeutics shares in Q3 2026, an estimated $1.47M.
- CytomX Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2759 holding.
- Barclays first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 31 quarters since.
- 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.